| abstract |
The present invention relates to a Benix nokitake cyclohexane ketone compound for use in the treatment of autoimmune diseases. 4-Hydroxy-2,3-dimethoxy-6-methyl-5 (3,7,11-trimethyl-2,6,10-trienyl) -2-cyclohexaneketone isolated from Benix noctum extract (4-hydroxy-2,3-dimethoxy-6-methy-5 (3,7,11-trimethyl-dodeca-2,6,10-trienyl) -cyclohex-2-enone) and self such as systemic lupus erythematosus Symptoms caused by immune diseases can be effectively alleviated. Benixonochata cyclohexane ketone compound in the present invention helps to reduce the urinary protein content and blood antinuclear antibody concentration in mammals separating systemic lupus erythematosus, thereby reducing kidney inflammation and lesions, and antinuclear antibody Reduce injury to self-organization. Thus, the effect of treating autoimmune diseases such as systemic lupus erythematosus and kidney-related diseases caused by natural and side-effect-free substances is achieved. [Selection] Figure 2 |